← Back to Analyst Consensus 
IMRX Buy
Immuneering Corp
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 6, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Jul 20, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 8, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| May 19, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 9, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Nov 13, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| Oct 31, 2025 | Leerink Partners | initiate | — → Outperform | $15 | 50% |
| Sep 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Sep 26, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| Sep 25, 2025 | Oppenheimer | maintain | Outperform → Outperform | $30 | 52% |
| Sep 15, 2025 | Needham | maintain | Buy → Buy | $11 | 50% |
| Aug 26, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Aug 14, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Jun 18, 2025 | Mizuho | maintain | Outperform → Outperform | $10 | 52% |
| Jun 18, 2025 | Needham | reiterate | Buy → Buy | $9 | 50% |
| Jun 18, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Jun 5, 2025 | Needham | reiterate | Buy → Buy | $9 | 50% |
| May 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $21 | 52% |
| May 6, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Apr 10, 2025 | Needham | reiterate | Buy → Buy | $12 | 50% |
| Mar 24, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Mar 21, 2025 | Needham | reiterate | Buy → Buy | $12 | 50% |
| Feb 6, 2025 | Needham | reiterate | Buy → Buy | $12 | 50% |
| Jan 13, 2025 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Jan 8, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Jan 7, 2025 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Nov 20, 2024 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Nov 14, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Sep 13, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Aug 7, 2024 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Aug 7, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| May 8, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Apr 12, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Apr 2, 2024 | Mizuho | maintain | Buy → Buy | $8 | 52% |
| Mar 15, 2024 | Jefferies | downgrade | Buy → Hold | $3 | 52% |
| Mar 15, 2024 | Chardan Capital | maintain | Buy → Buy | $16 | 47% |
| Mar 15, 2024 | Needham | maintain | Buy → Buy | $15 | 50% |
| Mar 15, 2024 | TD Cowen | downgrade | Outperform → Market Perform | $0 | 54% |
| Mar 14, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Mar 11, 2024 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Mar 5, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $25 | 52% |
| Mar 4, 2024 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Feb 1, 2024 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Dec 1, 2023 | Needham | initiate | — → Buy | $20 | 50% |
| Aug 8, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $25 | 52% |
| Aug 7, 2023 | Chardan Capital | reiterate | Buy → Buy | $22 | 47% |
| Aug 4, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $14 | 54% |
| Apr 19, 2023 | Morgan Stanley | upgrade | Underweight → Equal-Weight | $14 | 54% |
| Apr 19, 2023 | Mizuho | upgrade | Neutral → Buy | $20 | 52% |
| Apr 19, 2023 | Chardan Capital | maintain | — → Buy | $22 | 47% |
Price Target Trend
Apr 20, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days